Difference between revisions of "Bcr - Breakpoint cluster region"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 44: | Line 44: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:26, 10 March 2015
| Bcr - Breakpoint cluster region | |
|---|---|
| Substrate peptide name | Breakpoint cluster region protein |
| Synonyms | Bcr |
| Determination type | In situ |
| Source | Homo sapiens (HPAEC) |
| Subcellular localization | Cytosol |
| Swissprot ID | P11247 |
| Reactive glutamines | Not determined yet - N terminal oligomerization domain |
| Reactive lysines | Not determined yet - N terminal oligomerization domain |
| Substrate sequence | Not determined yet - in the 1-62 amino acid containing region |
| Structure | 1K1F |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:21310073 |
| Notes | |
